Anna-Barbara Moscicki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna-Barbara Moscicki has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Sepideh Farhat
Department of Pediatrics, Division of Adolescent Medicine, University of California, San Francisco, CA, USA
4 shared publications- Andreas Martin Kaufmann
Department of Gynecology, HPV Research Laboratory, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
3 shared publications Jonathan S. Russell
Center for Biostatistics in AIDS Research (CBAR), Harvard T.H. Chan School of Public Health, Boston, MA, USA
3 shared publications- Margaret Stanley
Department of Pathology, University of Cambridge, Cambridge, United Kingdom
3 shared publications Mark I. Ryder
Department of Orofacial Sciences, School of Dentistry, University of California, San Francisco, CA, USA
3 shared publications- Neerja Bhatla
All India Institute of Medical Sciences New Delhi India
3 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1954769
Cervicovaginal lipid mediator profiles during high-risk HPV infection associated with subsequent viral clearance or persistence: an exploratory pilot study
Background: High-risk human papillomavirus (HPV) infection is the primary cause of cervical cancer, whereas most infections are spontaneously cleared. Although local immune and microbial factors associated with HPV outcomes have been investigated, the contribution of lipid mediators within the cervicovaginal microenvironment remains poorly characterized. Methods: Cervicovaginal wash samples from 30 participants in a prospective longitudinal HPV cohort were analyzed by targeted liquid chromatography–tandem mass spectrometry. Samples were obtained from HPV-negative women, HPV-positive women who were negative for the relevant HPV type at the subsequent visit (subsequent-clearance group), and HPV-positive women in whom the same HPV type remained detectable at the subsequent visit. Results: Six lipid mediators were detected in cervicovaginal wash samples. During HPV infection, women with subsequent clearance had higher measured concentrations of total 12-HETE and total 14-HDHA than HPV-negative women. In the secondary percentage-based analysis, the relative contribution of PGE 2 was lower in the subsequent-clearance group than in both the HPV-negative and subsequent-persistence groups, while the relative contribution of total 14-HDHA was higher in the subsequent-persistence group than in HPV-negative women. Direct comparison of correlation coefficients identified an opposite TxB 2 –14-HDHA relationship in subsequent clearance and persistence. Conclusions: Higher cervicovaginal concentrations of total 12-HETE and total 14-HDHA during HPV infection were associated with clearance of the relevant HPV type at the subsequent visit. The opposite TxB 2 –total 14-HDHA associations observed in subsequent clearance and persistence further suggest outcome-associated differences in lipid-mediator coordination. These exploratory findings identify lipid mediators as candidate correlates of HPV outcomes.
- 23 October 2026
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 16, 1954769
Open AccessCervicovaginal lipid mediator profiles during high-risk HPV infection associated with subsequent viral clearance or persistence: an exploratory pilot study
Background: High-risk human papillomavirus (HPV) infection is the primary cause of cervical cancer, whereas most infections are spontaneously cleared. Although local immune and microbial factors associated with HPV outcomes have been investigated, the contribution of lipid mediators within the cervicovaginal microenvironment remains poorly characterized. Methods: Cervicovaginal wash samples from 30 participants in a prospective longitudinal HPV cohort were analyzed by targeted liquid chromatography–tandem mass spectrometry. Samples were obtained from HPV-negative women, HPV-positive women who were negative for the relevant HPV type at the subsequent visit (subsequent-clearance group), and HPV-positive women in whom the same HPV type remained detectable at the subsequent visit. Results: Six lipid mediators were detected in cervicovaginal wash samples. During HPV infection, women with subsequent clearance had higher measured concentrations of total 12-HETE and total 14-HDHA than HPV-negative women. In the secondary percentage-based analysis, the relative contribution of PGE 2 was lower in the subsequent-clearance group than in both the HPV-negative and subsequent-persistence groups, while the relative contribution of total 14-HDHA was higher in the subsequent-persistence group than in HPV-negative women. Direct comparison of correlation coefficients identified an opposite TxB 2 –14-HDHA relationship in subsequent clearance and persistence. Conclusions: Higher cervicovaginal concentrations of total 12-HETE and total 14-HDHA during HPV infection were associated with clearance of the relevant HPV type at the subsequent visit. The opposite TxB 2 –total 14-HDHA associations observed in subsequent clearance and persistence further suggest outcome-associated differences in lipid-mediator coordination. These exploratory findings identify lipid mediators as candidate correlates of HPV outcomes.
- Open Access
- 28 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (3) , 638-644
Extended HPV typing as an efficient alternative within HPV ‐based screening programs
Extended high‐risk human papilloma virus (hrHPV) typing emerges as a potential alternative for detecting cervical intraepithelial neoplasia 3 (CIN3), without additional triage tests. We evaluate the extended hrHPV typing as an alternative to improve CIN3 detection within an HPV‐based screening program. Between January 2017 and August 2018, 5856 women aged 25–65 years were screened as part of a public cervical cancer screening program of the Tlalpan Sanitary Jurisdiction in Mexico City. HPV testing was performed by BD Onclarity™, which individually detects hrHPV types 16, 18, 31, 45, 51, and 52, and pools of types 33/58, 56/59/66, and 35/39/68. Specific hrHPV types within these pools were further identified using the Atila AmpFire platform. All HPV‐positive women ( n = 691) were referred to colposcopy evaluation for diagnostic confirmation. Of these, 561 women completed both colposcopy and histological confirmation, representing our analytical sample. HPV‐16 alone had a sensitivity of 43.0% and specificity of 85.4% for CIN3 detection. Sequentially adding HPV‐18/33/31/39 increased sensitivity to 100% for CIN3 detection, although with lower specificity (54.5%). The proportion of HPV‐16/18/33/31/39 positive women was 47.0%, with a CIN3 PPV 5.3%. Extended genotyping with HPV‐16/18/33/31/39 achieved 100% sensitivity for CIN3 detection, but a moderate specificity. This strategy aligns with the international recommendation for colposcopy referral in women with a PPV of CIN3 larger than 4.0%.
- 28 March 2026
- Published by Wiley in International Journal of Cancer
- Vol. 159 (3) , 638-644
Open AccessExtended HPV typing as an efficient alternative within HPV ‐based screening programs
Extended high‐risk human papilloma virus (hrHPV) typing emerges as a potential alternative for detecting cervical intraepithelial neoplasia 3 (CIN3), without additional triage tests. We evaluate the extended hrHPV typing as an alternative to improve CIN3 detection within an HPV‐based screening program. Between January 2017 and August 2018, 5856 women aged 25–65 years were screened as part of a public cervical cancer screening program of the Tlalpan Sanitary Jurisdiction in Mexico City. HPV testing was performed by BD Onclarity™, which individually detects hrHPV types 16, 18, 31, 45, 51, and 52, and pools of types 33/58, 56/59/66, and 35/39/68. Specific hrHPV types within these pools were further identified using the Atila AmpFire platform. All HPV‐positive women ( n = 691) were referred to colposcopy evaluation for diagnostic confirmation. Of these, 561 women completed both colposcopy and histological confirmation, representing our analytical sample. HPV‐16 alone had a sensitivity of 43.0% and specificity of 85.4% for CIN3 detection. Sequentially adding HPV‐18/33/31/39 increased sensitivity to 100% for CIN3 detection, although with lower specificity (54.5%). The proportion of HPV‐16/18/33/31/39 positive women was 47.0%, with a CIN3 PPV 5.3%. Extended genotyping with HPV‐16/18/33/31/39 achieved 100% sensitivity for CIN3 detection, but a moderate specificity. This strategy aligns with the international recommendation for colposcopy referral in women with a PPV of CIN3 larger than 4.0%.
- 16 February 2026
- Published by Springer Nature
- Vol. 448, 59-80
Microbiome, Human Papillomavirus and Cervical Carcinogenesis
The microbiome describes the collection of genes derived from microorganisms that live in body systems. After the discovery of Lactobacilli as important for vaginal health, the vaginal microbiome was initially binarily classified into healthy or bacterial vaginosis (BV), before being further explored using 16S sequencing and the development of community state types (CST) by Ravel et al. There are a plethora of studies describing the vaginal microbiome composition in relation to cervical disease outcomes, more specifically human papillomavirus infection and persistence, cervical preinvasive and invasive disease. While there is some conflicting evidence, the general consensus is that Lactobacillus spp., in particular Lactobacillus crispatus or CST I, is associated with healthy status, and BV, CST IV and Lactobacillus depletion are associated with cervical intraepithelial neoplasia. What constitutes a ‘normal’ vaginal microbiome is not clear; in Ravel’s study, around a quarter of women had CST I, and a quarter had CST IV. Although directionality is not established, mechanistic studies suggest immunomodulation and support biological plausibility. More recently, prebiotics and probiotics have been studied and there is some emerging evidence that this may be associated with increased clearance of cytological abnormalities. Important future work includes larger longitudinal studies, patient-derived organoids to examine causality and mechanistic insights, and development and trial of novel therapeutic treatments.
- 16 February 2026
- Published by Springer Nature
- Vol. 448, 59-80
Microbiome, Human Papillomavirus and Cervical Carcinogenesis
The microbiome describes the collection of genes derived from microorganisms that live in body systems. After the discovery of Lactobacilli as important for vaginal health, the vaginal microbiome was initially binarily classified into healthy or bacterial vaginosis (BV), before being further explored using 16S sequencing and the development of community state types (CST) by Ravel et al. There are a plethora of studies describing the vaginal microbiome composition in relation to cervical disease outcomes, more specifically human papillomavirus infection and persistence, cervical preinvasive and invasive disease. While there is some conflicting evidence, the general consensus is that Lactobacillus spp., in particular Lactobacillus crispatus or CST I, is associated with healthy status, and BV, CST IV and Lactobacillus depletion are associated with cervical intraepithelial neoplasia. What constitutes a ‘normal’ vaginal microbiome is not clear; in Ravel’s study, around a quarter of women had CST I, and a quarter had CST IV. Although directionality is not established, mechanistic studies suggest immunomodulation and support biological plausibility. More recently, prebiotics and probiotics have been studied and there is some emerging evidence that this may be associated with increased clearance of cytological abnormalities. Important future work includes larger longitudinal studies, patient-derived organoids to examine causality and mechanistic insights, and development and trial of novel therapeutic treatments.
- 6 October 2025
- Published by Wiley in International Journal of Eating Disorders
- Vol. 59 (1) , 122-133
Self‐Reported Physical Activity Energy Expenditure in Patients With Anorexia Nervosa: A Cross‐Sectional Analysis at Hospital Admission From the Study of Refeeding to Optimize iNpatient Gains
Objective: Elevated physical activity is a feature of anorexia nervosa (AN), often associated with poorer clinical outcomes. Less is known about how physical activity energy expenditure (PAEE) prior to hospital admission relates to illness severity at presentation. Method: Secondary data analysis of the Study of Refeeding to Optimize Inpatient Gains, a randomized controlled trial comparing inpatient refeeding approaches in AN and atypical AN. Upon admission, patients self‐reported: physical activity (past 7 days), Eating Disorder Examination–Questionnaire (EDE‐Q), anxiety (GAD‐7), depression (PHQ‐A), distress tolerance (DTS), and menstrual status. Medical instability (heart rate and systolic blood pressure, orthostasis, electrolyte abnormalities) was assessed. PAEE was calculated by multiplying the activity‐specific Metabolic Equivalent of Task (MET, kcal/kg/h) by the number of hours per activity; weekly METs for all activities were summed and averaged to obtain mean METs/day, then multiplied by admission body weight (kg) to obtain PAEE (kcal/d). Regressions assessed the association of PAEE and admission variables. Results: Physical activity data were available for 91 of 116 patients (56% with AN, 95% female), with M (SD) age = 16.6 (2.5) years and %median Body Mass Index = 84.6 (11.4). Across 37 recorded activities, PAEE was 354 (319) kcal/day. Higher PAEE was associated with older age, longer duration of weight loss, higher eating restraint (EDE‐Q; β = 0.17, p = 0.04), and anxiety (GAD‐7; β = 0.57, p = 0.04), but not with markers of medical instability. Discussion: Patients with high PAEE may need additional psychological support for anxiety and eating disorder cognitions during hospital admission. Further research is needed to understand how pre‐admission PAEE relates to long‐term recovery. Public Significance Statement: Patients with anorexia nervosa (AN) and atypical AN often report increased physical activity (PA). The extent to which energy expended in PA impacts indices of illness severity in the acute phase of illness is less well understood, especially among those who are subsequently hospitalized. Findings suggest patients expending greater energy in PA prior to admission may benefit from additional support to manage higher anxiety and eating restraint while in hospital. Trial Registration: ClinicalTrials.gov identifier: NCT02488109
- 6 October 2025
- Published by Wiley in International Journal of Eating Disorders
- Vol. 59 (1) , 122-133
Self‐Reported Physical Activity Energy Expenditure in Patients With Anorexia Nervosa: A Cross‐Sectional Analysis at Hospital Admission From the Study of Refeeding to Optimize iNpatient Gains
Objective: Elevated physical activity is a feature of anorexia nervosa (AN), often associated with poorer clinical outcomes. Less is known about how physical activity energy expenditure (PAEE) prior to hospital admission relates to illness severity at presentation. Method: Secondary data analysis of the Study of Refeeding to Optimize Inpatient Gains, a randomized controlled trial comparing inpatient refeeding approaches in AN and atypical AN. Upon admission, patients self‐reported: physical activity (past 7 days), Eating Disorder Examination–Questionnaire (EDE‐Q), anxiety (GAD‐7), depression (PHQ‐A), distress tolerance (DTS), and menstrual status. Medical instability (heart rate and systolic blood pressure, orthostasis, electrolyte abnormalities) was assessed. PAEE was calculated by multiplying the activity‐specific Metabolic Equivalent of Task (MET, kcal/kg/h) by the number of hours per activity; weekly METs for all activities were summed and averaged to obtain mean METs/day, then multiplied by admission body weight (kg) to obtain PAEE (kcal/d). Regressions assessed the association of PAEE and admission variables. Results: Physical activity data were available for 91 of 116 patients (56% with AN, 95% female), with M (SD) age = 16.6 (2.5) years and %median Body Mass Index = 84.6 (11.4). Across 37 recorded activities, PAEE was 354 (319) kcal/day. Higher PAEE was associated with older age, longer duration of weight loss, higher eating restraint (EDE‐Q; β = 0.17, p = 0.04), and anxiety (GAD‐7; β = 0.57, p = 0.04), but not with markers of medical instability. Discussion: Patients with high PAEE may need additional psychological support for anxiety and eating disorder cognitions during hospital admission. Further research is needed to understand how pre‐admission PAEE relates to long‐term recovery. Public Significance Statement: Patients with anorexia nervosa (AN) and atypical AN often report increased physical activity (PA). The extent to which energy expended in PA impacts indices of illness severity in the acute phase of illness is less well understood, especially among those who are subsequently hospitalized. Findings suggest patients expending greater energy in PA prior to admission may benefit from additional support to manage higher anxiety and eating restraint while in hospital. Trial Registration: ClinicalTrials.gov identifier: NCT02488109
- Open Access
- 3 June 2025
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 10 (1) , e70380
Correlation Between Technology and Improved Outcomes in Youth With Type 1 Diabetes Mellitus: Prospective Study Examining Outcomes for Patients With Depression and Those With Public Insurance
Background: Adherence to type 1 diabetes mellitus (T1DM) treatment regimens decreases during adolescence. While comorbid depression and health insurance disparities are individually known to potentiate this risk, technological devices for T1DM appear to be protective. Objective: We examined whether technology use impacted the association between depression and poorer health outcomes in T1DM. Given established insurance-based disparities based on technology access, we also studied whether the protective effects of T1DM technology differed among publicly and privately insured youth. Methods: Data were prospectively collected from pediatric patients with T1DM across 3 California medical centers. We used linear and negative binomial regression analyses to examine whether technology use was related to diabetes outcomes and whether this differed based on depression status (technology-by-depression interaction) and health insurance type (technology-by-insurance interaction). Results: Across 1573 patients aged 12 to 25 years (mean age 15.9, SD 2.9 years; n=1050, 66.4%, non-Hispanic White; n=745, 47.0% female), those with a depression diagnosis had higher hemoglobin A1c (HbA1c; mean 9.1%, SD 2.1% vs 10.1%, SD 2.2%) and more frequent diabetic ketoacidosis (DKA) events per year (mean 0.10, SD 0.36 vs 0.24, SD 0.66) than those without (P=.003). Patients using both a continuous glucose monitor (CGM) and pump had lower HbA1c levels and fewer DKA events per year (mean HbA1c 8.2%, SE 0.1%; mean DKA events per year 0.05, SE 0.01) than those using one device (mean HbA1c 9.0%, SE 0.1%; mean DKA events 0.08, SE 0.1%) or none (mean HbA1c 10.0%, SE 0.1%; mean DKA events 0.19, SE 0.1%; P<.001). While youth with public insurance had significantly higher HbA1c levels than those with commercial insurance (mean 9.3%, SD 2.1% vs 9.0%, SD 2.0%, P<.001), those using a CGM had no reliable decrease in HbA1c compared to their commercially insured peers (P=.35). Conclusions: Technology use in pediatric T1DM appears protective for both youth with a history of depression and those who are publicly insured. These data underscore the importance of universal access to technology to mitigate disparities based on comorbid mental health issues and differential access to care.
- 3 June 2025
- Published by JMIR Publications Inc. in JMIR Diabetes
- Vol. 10 (1) , e70380
Open AccessCorrelation Between Technology and Improved Outcomes in Youth With Type 1 Diabetes Mellitus: Prospective Study Examining Outcomes for Patients With Depression and Those With Public Insurance
Background: Adherence to type 1 diabetes mellitus (T1DM) treatment regimens decreases during adolescence. While comorbid depression and health insurance disparities are individually known to potentiate this risk, technological devices for T1DM appear to be protective. Objective: We examined whether technology use impacted the association between depression and poorer health outcomes in T1DM. Given established insurance-based disparities based on technology access, we also studied whether the protective effects of T1DM technology differed among publicly and privately insured youth. Methods: Data were prospectively collected from pediatric patients with T1DM across 3 California medical centers. We used linear and negative binomial regression analyses to examine whether technology use was related to diabetes outcomes and whether this differed based on depression status (technology-by-depression interaction) and health insurance type (technology-by-insurance interaction). Results: Across 1573 patients aged 12 to 25 years (mean age 15.9, SD 2.9 years; n=1050, 66.4%, non-Hispanic White; n=745, 47.0% female), those with a depression diagnosis had higher hemoglobin A1c (HbA1c; mean 9.1%, SD 2.1% vs 10.1%, SD 2.2%) and more frequent diabetic ketoacidosis (DKA) events per year (mean 0.10, SD 0.36 vs 0.24, SD 0.66) than those without (P=.003). Patients using both a continuous glucose monitor (CGM) and pump had lower HbA1c levels and fewer DKA events per year (mean HbA1c 8.2%, SE 0.1%; mean DKA events per year 0.05, SE 0.01) than those using one device (mean HbA1c 9.0%, SE 0.1%; mean DKA events 0.08, SE 0.1%) or none (mean HbA1c 10.0%, SE 0.1%; mean DKA events 0.19, SE 0.1%; P<.001). While youth with public insurance had significantly higher HbA1c levels than those with commercial insurance (mean 9.3%, SD 2.1% vs 9.0%, SD 2.0%, P<.001), those using a CGM had no reliable decrease in HbA1c compared to their commercially insured peers (P=.35). Conclusions: Technology use in pediatric T1DM appears protective for both youth with a history of depression and those who are publicly insured. These data underscore the importance of universal access to technology to mitigate disparities based on comorbid mental health issues and differential access to care.
- Open Access
- 13 January 2025
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 29 (2) , 168-179
Updated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection
Objective: The purpose of this review was to examine new evidence since the authors' 2019 guidelines for cervical cancer (CC) screening in non-HIV immunocompromised persons and to provide updated recommendations based on literature review and expert opinion. In addition, human papillomavirus (HPV) vaccine efficacy in these populations was reviewed. Methods: A literature search was performed similar to the authors' previous publication but was conducted through March 2023. Risk of CC, squamous intraepithelial lesions, and HPV infection in those living with solid organ transplant (SOT), end-stage renal disease (ESRD), hematopoietic stem cell transplant (HSCT), and autoimmune diseases (AID), specifically systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) with addition of multiple sclerosis (MS) were researched. This update also summarizes data available on newer disease-modifying therapies (DMTs) including monoclonal antibodies (MABs). The authors then made recommendations for HPV vaccine administration, and screening using either general population guidelines or increased surveillance, the latter based on following current recommendations for women living with HIV. Additionally, the literature search included antibody response to HPV vaccines and recommendations for their administration for these same conditions. Results: Based on the reviewed risks, evidence continued to support those persons living with SOT, ESRD, HSCT, and SLE, whether on immunosuppressant therapy or not, had an increased risk of HPV, squamous intraepithelial lesions, and CC whereas there was weak evidence that those persons with IBD, RA, and MS not on immunosuppressants were at risk. Data on persons using DMT/MAB were conflicting. Data showed that patients on certain immunosuppressants had lower antibody titers following HPV vaccination. There were no studies on HPV vaccine efficacy. Conclusions: Following US Center for Disease Control and Prevention HIV Cervical cancer screening (CCS) guidelines is recommended for the following: SOT, ESRD, HSCT, and SLE whether on immunosuppressants or not, and IBD, RA, and MS on immunosuppressants. Shared decision-making about increased surveillance for IBD and RA not on immunosuppressants and persons on any DMT or MAB is reasonable based on conflicting data. Human papillomavirus vaccination should not change the recommendations for increased CC surveillance. A 3-dose series of the HPV vaccine is recommended for all age-eligible patients starting at 9 years of age, with catch-up to 26 years of age. Vaccination from age 27 up to age 45 years per Advisory Committee on Immunization Practices guidelines should be considered in shared decision-making. When possible, HPV vaccine series should be initiated and completed before SOT or initiation of DMT/MAB. For HSCT, the vaccine series should be readministered along with other childhood vaccines.
- 13 January 2025
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 29 (2) , 168-179
Open AccessUpdated Review for Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection
Objective: The purpose of this review was to examine new evidence since the authors' 2019 guidelines for cervical cancer (CC) screening in non-HIV immunocompromised persons and to provide updated recommendations based on literature review and expert opinion. In addition, human papillomavirus (HPV) vaccine efficacy in these populations was reviewed. Methods: A literature search was performed similar to the authors' previous publication but was conducted through March 2023. Risk of CC, squamous intraepithelial lesions, and HPV infection in those living with solid organ transplant (SOT), end-stage renal disease (ESRD), hematopoietic stem cell transplant (HSCT), and autoimmune diseases (AID), specifically systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) with addition of multiple sclerosis (MS) were researched. This update also summarizes data available on newer disease-modifying therapies (DMTs) including monoclonal antibodies (MABs). The authors then made recommendations for HPV vaccine administration, and screening using either general population guidelines or increased surveillance, the latter based on following current recommendations for women living with HIV. Additionally, the literature search included antibody response to HPV vaccines and recommendations for their administration for these same conditions. Results: Based on the reviewed risks, evidence continued to support those persons living with SOT, ESRD, HSCT, and SLE, whether on immunosuppressant therapy or not, had an increased risk of HPV, squamous intraepithelial lesions, and CC whereas there was weak evidence that those persons with IBD, RA, and MS not on immunosuppressants were at risk. Data on persons using DMT/MAB were conflicting. Data showed that patients on certain immunosuppressants had lower antibody titers following HPV vaccination. There were no studies on HPV vaccine efficacy. Conclusions: Following US Center for Disease Control and Prevention HIV Cervical cancer screening (CCS) guidelines is recommended for the following: SOT, ESRD, HSCT, and SLE whether on immunosuppressants or not, and IBD, RA, and MS on immunosuppressants. Shared decision-making about increased surveillance for IBD and RA not on immunosuppressants and persons on any DMT or MAB is reasonable based on conflicting data. Human papillomavirus vaccination should not change the recommendations for increased CC surveillance. A 3-dose series of the HPV vaccine is recommended for all age-eligible patients starting at 9 years of age, with catch-up to 26 years of age. Vaccination from age 27 up to age 45 years per Advisory Committee on Immunization Practices guidelines should be considered in shared decision-making. When possible, HPV vaccine series should be initiated and completed before SOT or initiation of DMT/MAB. For HSCT, the vaccine series should be readministered along with other childhood vaccines.
- 27 August 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 190, 160-166
Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women
- 27 August 2024
- Published by Elsevier in Gynecologic Oncology
- Vol. 190, 160-166
Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women
- Open Access
- 21 March 2022
- Published by Springer Nature in Cancer Causes & Control
- Vol. 33 (6) , 813-821
Impact of an educational tool on young women’s knowledge of cervical cancer screening recommendations
Purpose: Current cervical cancer screening guidelines recommend 3-year screening intervals, in contrast to the previous recommendation of annual screening, to prevent over screening and overtreatment. We evaluated the impact of viewing a tablet-based educational tool prior to seeing a clinician on young women’s knowledge and understanding of cervical cancer screening, HPV vaccination follow-up of abnormal pap smears, and comfort in communicating with their providers. Methods: This cross-sectional study was part of a cluster-randomized study of fourteen primary care clinics from January 2015 to December 2016. We developed the cervical cancer education tool in English and Spanish using a community-based approach that included formative work and cognitive interviewing. Clinics were randomized to use the intervention (tablet-based patient education tool) or to participate as a control group. We administered surveys to a convenience sample of 229 English- or Spanish-speaking women aged 19 to 35 years in these clinics. We used descriptive analyses and logistic regression models with cluster-robust standard errors to compare differences among the two groups. Results: Compared to women seen in control clinics, women seen in intervention clinics demonstrated greater knowledge regarding human papilloma virus (HPV (p = 0.004) and understanding (p < 0.001) of cervical cancer screening. Comfort in communicating with providers was not statistically different (p = 0.053). Women in the intervention group felt that the tool helped them understand that an abnormal Pap smear does not require immediate treatment (61.5%). Conclusion: Innovative online patient education that is offered prior to patients’ interaction with their clinicians can improve their knowledge about cervical cancer prevention and treatment.
- 21 March 2022
- Published by Springer Nature in Cancer Causes & Control
- Vol. 33 (6) , 813-821
Open AccessImpact of an educational tool on young women’s knowledge of cervical cancer screening recommendations
Purpose: Current cervical cancer screening guidelines recommend 3-year screening intervals, in contrast to the previous recommendation of annual screening, to prevent over screening and overtreatment. We evaluated the impact of viewing a tablet-based educational tool prior to seeing a clinician on young women’s knowledge and understanding of cervical cancer screening, HPV vaccination follow-up of abnormal pap smears, and comfort in communicating with their providers. Methods: This cross-sectional study was part of a cluster-randomized study of fourteen primary care clinics from January 2015 to December 2016. We developed the cervical cancer education tool in English and Spanish using a community-based approach that included formative work and cognitive interviewing. Clinics were randomized to use the intervention (tablet-based patient education tool) or to participate as a control group. We administered surveys to a convenience sample of 229 English- or Spanish-speaking women aged 19 to 35 years in these clinics. We used descriptive analyses and logistic regression models with cluster-robust standard errors to compare differences among the two groups. Results: Compared to women seen in control clinics, women seen in intervention clinics demonstrated greater knowledge regarding human papilloma virus (HPV (p = 0.004) and understanding (p < 0.001) of cervical cancer screening. Comfort in communicating with providers was not statistically different (p = 0.053). Women in the intervention group felt that the tool helped them understand that an abnormal Pap smear does not require immediate treatment (61.5%). Conclusion: Innovative online patient education that is offered prior to patients’ interaction with their clinicians can improve their knowledge about cervical cancer prevention and treatment.
- 25 June 2021
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 19 (3) , 1-4
Natural History of HPV Infection Latency and Clearance
- 25 June 2021
- Published by Springer Nature in Indian Journal of Gynecologic Oncology
- Vol. 19 (3) , 1-4
Natural History of HPV Infection Latency and Clearance
- 1 May 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 60 (5) , 666-673
Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence
- 1 May 2021
- Published by Elsevier in American Journal of Preventive Medicine
- Vol. 60 (5) , 666-673
Effect of 2 Interventions on Cervical Cancer Screening Guideline Adherence